Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is ...
Athersys reported revenue of $5.33 million for fiscal year 2022, down 3.4% from fiscal year 2021, and net income of -$72.53 million. In Q3 2023 (the quarter ended September 30, 2023) revenue was $0, down 100.0% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2022.
From state WARN notices, SEC filings and news reports. Reported: news reports only. Confirmed: an official filing exists.
Athersys had 0 layoffs in the last 12 months, and 2 in all (the earliest dated June 2, 2022).
Layoffs, 12 months
0
Workers not stated
Layoffs in all
2
Earliest dated Jun 2, 2022
Workers in all
-
Where the sources state it
Newest layoff
Dec 22, 2023
Announced date
| Date | Place | Workers | Status | Sources |
|---|---|---|---|---|
| Dec 22, 2023 | United States | not stated | Confirmed | SEC 8-K |
| Jun 2, 2022 | United States | not stated | Confirmed | SEC 8-K |
No profile data available.